Protagonist Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Protagonist Therapeutics Inc (PTGX)

Q3 202624 Jun – 7 Sep 2026

▲3

PTGX re-rated as rusfertide wins FDA approval and cash pours in

Rusfertide (MIMRYLO) approved by FDA The FDA approved rusfertide, now MIMRYLO, for polycythemia vera, a blood cancer. This is the big one: a drug Protagonist discovered is now sellable, and approval triggered $275 million in payments from partner Takeda, with up to $875 million more possible plus royalties of 14% to 29% on sales.
The approval is the single largest new event and directly changes PTGX's revenue outlook.
Company swings to profit on milestone cash Second-quarter results flipped from a $34.8 million loss to a $162.8 million profit, helped by a $50 million payment from Johnson & Johnson for psoriasis drug ICOTYDE and $200 million from Takeda. Cash stands at $849.5 million. But most of that revenue is one-time milestone money, not repeatable product sales, and research costs are expected to rise.
It shows the financial effect of the deals and gives the honest counterweight that the profit is not repeatable.
ICOTYDE launch and pipeline expansion Partner Johnson & Johnson reports a strong launch of ICOTYDE, the once-daily pill for plaque psoriasis, which J&J says could become its biggest product ever. Protagonist gets royalties and up to $580 million more in milestones. The drug also met its goal in a mid-stage ulcerative colitis trial, opening a second large market.
It is the main recurring royalty stream and shows the partnered drug reaching new uses.
Royalty choice trades control for steady income Protagonist gave up its 50:50 U.S. profit share with Takeda in exchange for royalties of 14% to 29% on worldwide sales. That means steadier, simpler income but no control over pricing or market access, and the remaining $875 million in milestones depends on the drug selling well.
It explains the trade-off behind the deal structure that shapes future PTGX earnings.

July 202624 Jun – 7 Sep 2026

▲3

PTGX re-rated as rusfertide wins FDA approval and cash pours in

Rusfertide (MIMRYLO) approved by FDA The FDA approved rusfertide, now MIMRYLO, for polycythemia vera, a blood cancer. This is the big one: a drug Protagonist discovered is now sellable, and approval triggered $275 million in payments from partner Takeda, with up to $875 million more possible plus royalties of 14% to 29% on sales.
The approval is the single largest new event and directly changes PTGX's revenue outlook.
Company swings to profit on milestone cash Second-quarter results flipped from a $34.8 million loss to a $162.8 million profit, helped by a $50 million payment from Johnson & Johnson for psoriasis drug ICOTYDE and $200 million from Takeda. Cash stands at $849.5 million. But most of that revenue is one-time milestone money, not repeatable product sales, and research costs are expected to rise.
It shows the financial effect of the deals and gives the honest counterweight that the profit is not repeatable.
ICOTYDE launch and pipeline expansion Partner Johnson & Johnson reports a strong launch of ICOTYDE, the once-daily pill for plaque psoriasis, which J&J says could become its biggest product ever. Protagonist gets royalties and up to $580 million more in milestones. The drug also met its goal in a mid-stage ulcerative colitis trial, opening a second large market.
It is the main recurring royalty stream and shows the partnered drug reaching new uses.
Royalty choice trades control for steady income Protagonist gave up its 50:50 U.S. profit share with Takeda in exchange for royalties of 14% to 29% on worldwide sales. That means steadier, simpler income but no control over pricing or market access, and the remaining $875 million in milestones depends on the drug selling well.
It explains the trade-off behind the deal structure that shapes future PTGX earnings.

Latest24 Jun – 7 Sep 2026

▲3

PTGX re-rated as rusfertide wins FDA approval and cash pours in

Rusfertide (MIMRYLO) approved by FDA The FDA approved rusfertide, now MIMRYLO, for polycythemia vera, a blood cancer. This is the big one: a drug Protagonist discovered is now sellable, and approval triggered $275 million in payments from partner Takeda, with up to $875 million more possible plus royalties of 14% to 29% on sales.
The approval is the single largest new event and directly changes PTGX's revenue outlook.
Company swings to profit on milestone cash Second-quarter results flipped from a $34.8 million loss to a $162.8 million profit, helped by a $50 million payment from Johnson & Johnson for psoriasis drug ICOTYDE and $200 million from Takeda. Cash stands at $849.5 million. But most of that revenue is one-time milestone money, not repeatable product sales, and research costs are expected to rise.
It shows the financial effect of the deals and gives the honest counterweight that the profit is not repeatable.
ICOTYDE launch and pipeline expansion Partner Johnson & Johnson reports a strong launch of ICOTYDE, the once-daily pill for plaque psoriasis, which J&J says could become its biggest product ever. Protagonist gets royalties and up to $580 million more in milestones. The drug also met its goal in a mid-stage ulcerative colitis trial, opening a second large market.
It is the main recurring royalty stream and shows the partnered drug reaching new uses.
Royalty choice trades control for steady income Protagonist gave up its 50:50 U.S. profit share with Takeda in exchange for royalties of 14% to 29% on worldwide sales. That means steadier, simpler income but no control over pricing or market access, and the remaining $875 million in milestones depends on the drug selling well.
It explains the trade-off behind the deal structure that shapes future PTGX earnings.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.